{
  "templates": [
    {
      "id": "fda-ae-detailed-001",
      "title": "Table 14.3.1 Summary of Adverse Events",
      "type": "table",
      "path": "fda_templates\\fda_ae_detailed_001.json",
      "keywords": [
        "table",
        "summary",
        "adverse",
        "events"
      ]
    },
    {
      "id": "fda-baseline-characteristics-detailed-001",
      "title": "Table 14.1.3 Baseline Characteristics",
      "type": "table",
      "path": "fda_templates\\fda_baseline_characteristics_detailed_001.json",
      "keywords": [
        "table",
        "baseline",
        "characteristics"
      ]
    },
    {
      "id": "fda-demographic-detailed-001",
      "title": "Table 14.1.1 Demographic and Baseline Characteristics Summary",
      "type": "table",
      "path": "fda_templates\\fda_demographic_detailed_001.json",
      "keywords": [
        "table",
        "demographic",
        "baseline",
        "characteristics",
        "summary"
      ]
    },
    {
      "id": "fda-disposition-detailed-001",
      "title": "Table 14.1.2 Subject Disposition",
      "type": "table",
      "path": "fda_templates\\fda_disposition_detailed_001.json",
      "keywords": [
        "table",
        "subject",
        "disposition"
      ]
    },
    {
      "id": "fda-ecg-detailed-001",
      "title": "Table 14.3.4 ECG Evaluations Summary",
      "type": "table",
      "path": "fda_templates\\fda_ecg_detailed_001.json",
      "keywords": [
        "table",
        "ecg",
        "evaluations",
        "summary"
      ]
    },
    {
      "id": "fda-efficacy-detailed-001",
      "title": "Table 14.2.1 Primary Efficacy Endpoint Analysis",
      "type": "table",
      "path": "fda_templates\\fda_efficacy_detailed_001.json",
      "keywords": [
        "table",
        "primary",
        "efficacy",
        "endpoint",
        "analysis"
      ]
    },
    {
      "id": "fda-exposure-response-detailed-001",
      "title": "Table 14.2.5 Exposure-Response Analysis",
      "type": "table",
      "path": "fda_templates\\fda_exposure_response_detailed_001.json",
      "keywords": [
        "table",
        "exposure",
        "response",
        "analysis"
      ]
    },
    {
      "id": "fda-laboratory-detailed-001",
      "title": "Table 14.3.3 Laboratory Evaluations Summary",
      "type": "table",
      "path": "fda_templates\\fda_laboratory_detailed_001.json",
      "keywords": [
        "table",
        "laboratory",
        "evaluations",
        "summary"
      ]
    },
    {
      "id": "fda-lab-shifts-detailed-001",
      "title": "Table 14.3.5 Laboratory Shifts Analysis",
      "type": "table",
      "path": "fda_templates\\fda_lab_shifts_detailed_001.json",
      "keywords": [
        "table",
        "laboratory",
        "shifts",
        "analysis"
      ]
    },
    {
      "id": "fda-medical-history-detailed-001",
      "title": "Table 14.1.2 Medical History",
      "type": "table",
      "path": "fda_templates\\fda_medical_history_detailed_001.json",
      "keywords": [
        "table",
        "medical",
        "history"
      ]
    },
    {
      "id": "fda-pk-detailed-001",
      "title": "Table 14.4.1 Pharmacokinetic Parameters Summary",
      "type": "table",
      "path": "fda_templates\\fda_pk_detailed_001.json",
      "keywords": [
        "table",
        "pharmacokinetic",
        "parameters",
        "summary"
      ]
    },
    {
      "id": "fda-qol-pro-detailed-001",
      "title": "Table 14.2.4 Quality of Life and Patient Reported Outcomes",
      "type": "table",
      "path": "fda_templates\\fda_qol_pro_detailed_001.json",
      "keywords": [
        "table",
        "quality",
        "life",
        "patient",
        "reported",
        "outcomes"
      ]
    },
    {
      "id": "fda-responder-analysis-detailed-001",
      "title": "Table 14.2.3 Responder Analysis",
      "type": "table",
      "path": "fda_templates\\fda_responder_analysis_detailed_001.json",
      "keywords": [
        "table",
        "responder",
        "analysis"
      ]
    },
    {
      "id": "fda-secondary-efficacy-detailed-001",
      "title": "Table 14.2.2 Secondary Efficacy Endpoints Analysis",
      "type": "table",
      "path": "fda_templates\\fda_secondary_efficacy_detailed_001.json",
      "keywords": [
        "table",
        "secondary",
        "efficacy",
        "endpoints",
        "analysis"
      ]
    },
    {
      "id": "fda-sensitivity-analysis-detailed-001",
      "title": "Table 14.3.2 Sensitivity Analyses",
      "type": "table",
      "path": "fda_templates\\fda_sensitivity_analysis_detailed_001.json",
      "keywords": [
        "table",
        "sensitivity",
        "analyses"
      ]
    },
    {
      "id": "fda-subgroup-analysis-detailed-001",
      "title": "Table 14.3.1 Subgroup Analyses",
      "type": "table",
      "path": "fda_templates\\fda_subgroup_analysis_detailed_001.json",
      "keywords": [
        "table",
        "subgroup",
        "analyses"
      ]
    },
    {
      "id": "fda-vital-shifts-detailed-001",
      "title": "Table 14.3.6 Vital Signs Shifts Analysis",
      "type": "table",
      "path": "fda_templates\\fda_vital_shifts_detailed_001.json",
      "keywords": [
        "table",
        "vital",
        "signs",
        "shifts",
        "analysis"
      ]
    },
    {
      "id": "fda-vital-signs-detailed-001",
      "title": "Table 14.3.2 Vital Signs Summary",
      "type": "table",
      "path": "fda_templates\\fda_vital_signs_detailed_001.json",
      "keywords": [
        "table",
        "vital",
        "signs",
        "summary"
      ]
    }
  ]
}